Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland
ConclusionsT-DXd is cost-effective based on surrogate WTP thresholds of €72,000 and €139,000 per QALY.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Economics | Finland Health | Health Management | HER2 | Herceptin | Study